PAVmed Inc. (PAVM)

Name: PAVmed Inc. (PAVM) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: PAVmed Inc. (PAVM)

Stock Card

$5.21

$0.29 (5.89%)

As on 31-Aug-2026 16:00EDT

Market cap

$39 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

1.4

Div. Yield

0 %

PAVmed (PAVM) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 4.90 High: 5.21

52 Week Range

Low: 3.88 High: 28.44

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.6 %
ROCE

-- %
Industry P/E

44.46
EV/EBITDA

25.8
Debt to Equity

0
Book Value

$--
EPS

$-10
Face value

--
Shares outstanding

7,995,918

10 Years Aggregate

CFO

$-220.04 Mln

EBITDA

$-282.86 Mln

Net Profit

$-301.54 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
PAVmed (PAVM)	-21.3	3.1	-15.9	-64.2	-66.5	-72.4	-50.9
BSE Sensex^*	-9.1	-1.5	2.9	-3.6	5.9	6.0	10.5
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 31-Aug-2026 | *As on 01-Sep-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022	2021	2020	2019
PAVmed (PAVM)	-64.8	-84.5	-42.8	-80.5	16.0	76.7	24.7
S&P Small-Cap 600	4.0	7.0	13.9	-17.4	25.3	9.6	20.9
BSE Sensex	9.1	8.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
PAVmed (PAVM)	5.2	39.3	0.1	-12.1	-8,764.3	-26	--	1.4
10X Genomics Inc (TXG)	62.5	8,018.1	616.9	-75.1	1.7	-9.3	--	10.2
Avantor (AVTR)	14.5	9,638.1	6,561.1	-578.0	-4.5	-10.3	--	1.7
Bio-Rad Laboratories	365.1	9,761.6	2,589.3	222.4	-6.0	3	44.5	1.3
Bruker (BRKR)	58.0	8,696.7	3,499.6	-71.2	0.5	-3.2	--	3.8
Glaukos Corp (GKOS)	179.6	10,905.5	612.8	-188.1	-30.6	-28.1	--	16.4
Lantheus Holdings (LNTH)	101.0	6,577.5	1,556.3	275.3	24.6	22.9	24.1	5.0
Merit Medical Systems (MMSI)	90.7	5,403.2	1,579.2	145.6	14.3	8.9	37.2	3.2
Penumbra (PEN)	323.1	12,752.7	1,504.9	160.6	13.6	10.9	79.4	8.4
Repligen (RGEN)	181.0	9,947.9	785.1	41.5	9.9	2	251.8	4.9

Shareholding Pattern

View Details

About PAVmed (PAVM)

PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for... use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck device. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York. Read more

Chairman & CEO

Dr. Lishan Aklog M.D.
Chairman & CEO

Dr. Lishan Aklog M.D.
Headquarters

New York, NY
Website

https://www.pavmed.com

FAQs for PAVmed (PAVM)

What is the current share price of PAVmed Inc (PAVM) Today?

The share price of PAVmed Inc (PAVM) is $5.21 (NASDAQ) as of 31-Aug-2026 16:00 EDT. PAVmed Inc (PAVM) has given a return of -66.54% in the last 3 years.

What is the current PB & PE ratio of PAVmed Inc (PAVM)?

Since, TTM earnings of PAVmed Inc (PAVM) is negative, P/E ratio is not available.
The P/B ratio of PAVmed Inc (PAVM) is 1.36 times as on 28-Aug-2026, a 64 discount to its peers’ median range of 3.79 times.

PE & PB ratio at the end of financial year.